Belumosudil is a small-molecule drug developed as a targeted therapy for immune-related disorders. It was discovered and developed by Kadmon Corporation, focusing on treatments for chronic inflammatory and fibrotic diseases. The drug works by selectively inhibiting the Rho-associated coiled-coil kinase (ROCK) pathway, which plays an important role in immune regulation and tissue fibrosis. Belumosudil showed promising results in clinical trials for patients suffering from chronic graft-versus-host disease, particularly those who had failed multiple prior lines of therapy. Based on these results, it received approval from the U.S. Food and Drug Administration in 2021. The drug is marketed under the brand name Rezurock. Its introduction marked a significant advancement in the management of graft-versus-host disease by offering a new mechanism of action compared to traditional immunosuppressive treatments. Belumosudil is taken orally, making it convenient for long-term use in patients. Over time, it has gained attention for its dual anti-inflammatory and anti-fibrotic effects. Research is ongoing to explore its potential applications in other immune-mediated and fibrotic conditions.
